'Death mi' diaporamas de présentation

Do T irofiban A nd R eoPro G ive Similar E fficacy Outcomes T rial

Do T irofiban A nd R eoPro G ive Similar E fficacy Outcomes T rial. N Engl J Med 2001;344:1888-94. GP IIb/IIIa Inhibition in PCI. Consistent reduction in adverse events Optimal outcome when combined with stents No comparative data between agents. 0.0. 0.5. 1.0. 2.0. Background.

531 views • 43 slides

Dr Alex Chase

Bleeding Matters and How to Avoid It the radial approach. Dr Alex Chase. R ad I al V s. femor AL access for coronary intervention in patients with acute coronary syndromes study. 2006-2010. anecdotes. Fact 1. Bleeding is Bad. Fact 2 Radial reduces bleeding and transfusion.

483 views • 35 slides

Completeness of Follow

426 views • 35 slides

The Role of Platelets in Atherothrombosis

The Role of Platelets in Atherothrombosis. Adhesion. Aggregation (GP IIb/IIIa Inhibitors). 1. 3. Activated Gpllb/llla. Fibrinogen. von Willebrand Factor/Gplb bind. Platelets. Collagen Gpla/lla bind. Lipid core. Platelet Plug. Activation (Clopidogrel). 2. 4. Thrombin. PF4. ADP.

721 views • 34 slides

491 views • 33 slides

857 views • 33 slides

Clinical Trials of GP IIb/IIIa Inhibition

Clinical Trials of GP IIb/IIIa Inhibition. Major Trials of GP IIb/IIIa Inhibitors in ACS GP IIb/IIIa Inhibitors in PCI GP IIb/IIIa Inhibition in Patients With Diabetes. Clinical Trials of GP IIb/IIIa Inhibition. Major Trials of GP IIb/IIIa Inhibitors in ACS.

574 views • 28 slides

La preparazione alla PTCA nelle sindromi coronariche acute Area Emergenza Urgenza ANMCO

La preparazione alla PTCA nelle sindromi coronariche acute Area Emergenza Urgenza ANMCO Roma 20 marzo 2010 La preparazione farmacologica alla PTCA : trattamento antiaggregante/anticoagulante precoce o in sala di emodinamica? Cesare Greco Cardiologia III Ospedale S Giovanni- Roma.

442 views • 23 slides

Disclosures

267 views • 22 slides

Tracy Wang, MD, MHS, MSc on behalf of

Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients with Acute Coronary Syndrome: an Analysis from the EARLY-ACS Trial. Tracy Wang, MD, MHS, MSc on behalf of

261 views • 19 slides

OASIS-5

383 views • 18 slides

Cooling Off? Early Intervention? Very Early Intervention?

Cooling Off? Early Intervention? Very Early Intervention?. Steve Holmberg Sussex Cardiac Centre. NO CONFLICT OF INTEREST TO DECLARE. Invasive Strategy in ACS - is there still a debate?. ICTUS No benefit of invasive strategy out to 5 years

369 views • 18 slides

Clopidogrel Use and Death/MI After Stent Implantation in a Diabetic Population

296 views • 18 slides

None of the authors have any conflicts of interest in relation to the presentation

317 views • 17 slides

Benjamin Scirica, MD MPH Investigator, TIMI Study Group

327 views • 17 slides

ST Segment Resolution After Fibrinolysis for STEMI

TIMI ECG Core Laboratory. ST Segment Resolution After Fibrinolysis for STEMI. 180 minutes. Calculating ST Resolution Anterior MI Sum (ST elev in V1-V6,I,aVL) + Sum (ST dep in II, III, aVF) Inferior MI Sum (ST elev in II, III, aVF) + Sum (ST dep in V1-V4) ST Resolution Sum STdev at f/u

508 views • 5 slides

SYNERGY PCI A Subset analysis of the SYNERGY trial

SYNERGY PCI A Subset analysis of the SYNERGY trial. 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin. Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose.

203 views • 4 slides

SYNERGY PCI A Subset analysis of the SYNERGY trial

SYNERGY PCI A Subset analysis of the SYNERGY trial. 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin. Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose.

245 views • 4 slides

Sensitivity

Supplemental Fig. 3 Comparison of hs-cTnT and cTnI on admission for prediction of the combined endpoint death/MI (p=0.024) and death (p=0.093). Death/MI. Death. 100. 100. p=0.024. p=0.093. 80. 80. 60. 60. Sensitivity. Sensitivity. 40. 40. 20. hs-cTnT (AUC 0.66). 20.

152 views • 1 slides

NSTE- ACS

Death. Death/MI. Death. Death/MI. 18.4%. hsTnT<99th. TnI<99th. 25. 20. 21.8%. hsTnT>99th. TnI>99th. 15.8%. 18. 14.8%. 20. 16. 15%. 15.6%. 11.8%. 14. 15. 12. 9.9%. 11.9%. 10.4%. 8.5%. 8.9%. 10. 8. 10. 6. 4.3%. 4.6%. 4.3%. 4. 5. 2.3%. 2.3%. 1.2%. 0.4%. 0%.

169 views • 1 slides